Influence of Combined CYP3A4 and CYP3A5 Single-Nucleotide Polymorphisms on Tacrolimus Exposure in Kidney Transplant Recipients: A Study According to the Post-Transplant Phase

References

• Pirsch JD , MillerJ , DeierhoiMH , VincentiF , FiloRS . A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group . Transplantation63 ( 7 ), 977 – 983 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Thervet E , AnglicheauD , LegendreC , BeauneP . Role of pharmacogenetics of immunosuppressive drugs in organ transplantation . Ther. Drug Monit.30 ( 2 ), 143 – 150 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Daly AK . Significance of the minor cytochrome P450 3A isoforms . Clin. Pharmacokinet.45 ( 1 ), 13 – 31 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Rendic S . Summary of information on human CYP enzymes: human P450 metabolism data . Drug Metab. Rev.34 ( 1–2 ), 83 – 448 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Kuehl P , ZhangJ , LinYet al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression . Nat. Genet.27 ( 4 ), 383 – 391 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Hesselink DA , van SchaikRHN , van der HeidenIPet al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus . Clin. Pharmacol. Ther.74 ( 3 ), 245 – 54 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Wallemacq P , ArmstrongVW , BrunetMet al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference . Ther. Drug Monit.31 ( 2 ), 139 – 152 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Miller SA , DykesDD , PoleskyHF . A simple salting out procedure for extracting DNA from human nucleated cells . Nucleic Acids Res.16 ( 3 ), 1215 ( 1988 ).
   PubMed Web of Science ®Google Scholar
• Cavalli SA , HirataMH , HirataRD . Detection of MboII polymorphism at the 5′ promoter region of CYP3A4 . Clin. Chem.47 ( 2 ), 348 – 351 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Tsuchiya N , SatohS , TadaHet al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients . Transplantation78 ( 8 ), 1182 – 1187 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Hustert E , HaberlM , BurkOet al. The genetic determinants of the CYP3A5 polymorphism . Pharmacogenetics11 ( 9 ), 773 – 779 ( 2001 ).
   PubMedGoogle Scholar
• Walker AH , JaffeJM , GunasegaramSet al. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk . Hum. Mutat.12 ( 4 ), 89 ( 1998 ).
   PubMedGoogle Scholar
• Hsieh KP , LinYY , ChengCL . Novel mutations of CYP3A4 in Chinese . Drug Metab. Dispos.29 ( 3 ), 268 – 273 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Ball SE , ScatinaJ , KaoJet al. Population distribution and effects on drug metabolism of a genetic variant in the 59 promotor region of CYP3A4 . Clin. Pharmacol. Ther.66 ( 3 ), 288 – 294 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• García-Martín E , MartínezC , PizarroRMet al. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity . Clin. Pharmacol. Ther.71 ( 3 ), 196 – 204 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Paris PL , KupelianPA , HallJMet al. Association between a CYP3A4 genetic variant and clinical presentation in African–American prostate cancer patients . Cancer Epidemiol. Biomarkers Prev.8 ( 10 ), 901 – 905 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Sata F , SaponeA , ElizondoGet al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity . Clin. Pharmacol. Ther.67 ( 1 ), 48 – 56 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Ben Fredj N , ChaabaneA , ChadlyZet al. Tacrolimus therapeutic drug monitoring in Tunisian renal transplant recipients: effect of post-transplantation period . Transpl. Immunol.28 ( 4 ), 198 – 202 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Hesselink DA , van SchaikRHN , van der HeidenIPet al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus . Clin. Pharmacol. Ther.74 ( 3 ), 245 – 254 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Kuypers DRJ , de JongeH , NaesensM , LerutE , VerbekeK , Van RenterghemY . CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients . Clin. Pharmacol. Ther.82 ( 6 ), 711 – 725 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Ball SE , ScatinaJ , KaoJet al. Population distribution and effects on drug metabolism of a genetic variant in the 50 promoter region of CYP3A4 . Clin. Pharmacol. Ther.66 ( 3 ), 288 – 294 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Wandel C , WitteJS , HallJM , SteinCM , WoodAJ , WilkinsonGR . CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B50-promoter region polymorphism . Clin. Pharmacol. Ther.68 ( 1 ), 82 – 91 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Hesselink DA , van SchaikRH , van AgterenMet al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients . Pharmacogenet. Genomics18 ( 4 ), 339 – 348 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Gervasini G , GarciaM , MaciasRM , CuberoJJ , CaravacaF , BenitezJ . Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation . Transpl. Int.25 ( 4 ), 471 – 480 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Tavira B , CotoE , GarciáECet al. Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes . Clin. Chem. Lab. Med.49 ( 5 ), 825 – 833 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Zhao Y , SongM , GuanDet al. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus . Transplant. Proc.37 ( 1 ), 178 – 181 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Chakkera HA , ChangYH , BodnerJKet al. Genetic differences in Native Americans and tacrolimus dosing after kidney transplantation . Transplant. Proc.45 ( 1 ), 137 – 141 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Vannaprasaht S , ReungjuiS , SupanyaDet al. Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation . Clin. Ther.35 ( 11 ), 1762 – 1769 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• MacPhee IAM , HoltDW . A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype . Transplantation85 ( 2 ), 163 – 165 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Zhang J , ZhangX , LiuL , TongW . Value of CYP3A5 genotyping on determining initial dosages of tacrolimus for Chinese renal transplant recipients . Transplant. Proc.42 ( 9 ), 3459 – 3464 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Tang HL , XieHG , YaoY , HuYF . Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 non expressers than expressers . Pharmacogenet. Genomics21 ( 11 ), 713 – 720 ( 2011 ).
   PubMed Web of Science ®Google Scholar